Molecularly targeted therapy for metastatic colon cancer: Proven treatments and promising new agents

Christina Wu, Aline Charabaty, Michael Pishvaian, John L. Marshall

Research output: Contribution to journalReview articlepeer-review

Abstract

There has been a dramatic upsurge in the investigation of molecularly targeted therapy in colorectal cancer over the past two decades, with the first success being bevacizumab, a monoclonal antibody directed at vascular endothelial growth factor (VEGF). The latest additions to our armament are epidermal growth factor receptor (EGFR) inhibitors and the discovery of K-ras mutation's impact on treatment efficacy. This review summarizes the new therapies targeting established pathways, such as VEGF and EGFR, and introduces tyrosine kinase inhibitors and monoclonal antibodies, as well as exciting novel agents targeting insulin-like growth factor, tumor necrosis factor, the Sonic Hedgehog pathway, Src kinase, mammalian target of rapamycin, and protein kinase C, which already have shown activity in other cancers and are currently being studied in phase 1/2 trials in metastatic colorectal cancer.

Original languageEnglish (US)
Pages (from-to)193-198
Number of pages6
JournalCurrent Colorectal Cancer Reports
Volume6
Issue number4
DOIs
StatePublished - Oct 2010
Externally publishedYes

Keywords

  • Colorectal cancer
  • Metastatic
  • Molecular therapy
  • Targeted therapy

ASJC Scopus subject areas

  • Hepatology
  • Oncology
  • Gastroenterology

Fingerprint Dive into the research topics of 'Molecularly targeted therapy for metastatic colon cancer: Proven treatments and promising new agents'. Together they form a unique fingerprint.

Cite this